ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / IBRX / options
PCVX (49) KRYS (73) RGEN (61) TWST (47) ⌘ Pro Terminal β†’

ImmunityBio Inc. (IBRX) Options Positioning, Max Pain & Unusual Sweeps

$7.95 -4.10% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.88

ImmunityBio Inc. (IBRX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $8.79B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IBRX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is IBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, ImmunityBio Inc. (NASDAQ: IBRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $7.95 (-4.10% 1D, market cap $8.79B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IBRX ranks #619 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does IBRX compare to PCVX and KRYS in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IBRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.3%. By comparison, PCVX (Vaxcyte Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.76B) and KRYS (Krystal Biotech Inc.) posts a B grade (73/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.84B). Among the 5-stock peer group, KRYS leads on earnings multiple (46.9x) while KRYS leads on capital efficiency (16.5% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IBRX?
β–Ό

Per IBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326110), ImmunityBio Inc. generated $113.3M in revenue (+668.3% YoY), -$351.5M in net income, and -$308.8M in free cash flow against $501.9M in total assets and $450.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.88 (-0.93%)🧬 Dilution Drag (+1.92% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (34/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510034
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (4)Whales (8)SEC (8)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$13 Bull$7 Base$6 Bear
πŸ“¬ FREE IBRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for IBRX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
πŸ” WHY IBRX SCORES 34/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime Γ— Technicals: 57% of 52W Range β€’ RSI-14 at 44.3 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Whale & Options Positioning+8/20 pts (24% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
42
Grade D$9.91-12.8% Next Q
Q2 (-2Q)
39
Grade E$8.64+2% Next Q
Q3 (-1Q)
37
Grade E$8.81-9.8% Next Q
Current
34
Grade E$7.95-8.7% Hist 90D Ξ±
Trajectory: D (42) β†’ E (34)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a IBRX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While IBRX currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.75) and Max Pain ($8.35) forces dealer call-delta covering toward $13.05.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IBRXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œIBRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (IBRX)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for IBRX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IBRX)

  • βœ“Walkthrough of IBRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
IBRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.00%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $8.74H $8.74L $7.95C $7.95VOL 8.96M
RES: $11.22SUP: $7.87SMA50: $8.75SMA200: $7.95
$11.26$9.38$7.50$5.62$3.74RES $11.22SUP $7.87$7.952026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IBRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ IBRX Butterfly Map β†’ + Track IBRX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
22.3%/yr Implied 5Y Growth

vs. +668.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IBRX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for IBRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IBRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IBRX)

Health Care Rank #619 of 1015 βš”οΈ PCVX vs IBRX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (IBRX vs. PCVX, KRYS, RGEN, TWST)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ImmunityBio Inc. (IBRX) ranks #619 by composite RQD confidence (34/100, grade E) and #120 by equity capitalization ($8.79B). Within this direct 5-issuer industry benchmark cohort, KRYS leads on earnings valuation at 46.9x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and β€” gross margin. KRYS currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with IBRX at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IBRX ACTIVE
ImmunityBio Inc.
E 34/100 β€” 96.0% -27.3% -4.10% $8.79B Benchmark Subject
PCVX
Vaxcyte Inc.
D 49/100 β€” β€” -27.6% -2.27% $9.76B /pcvx-vs-ibrx β†’
KRYS
Krystal Biotech Inc.
B 73/100 46.9x β€” 16.5% -10.95% $9.84B /krys-vs-ibrx β†’
RGEN
Repligen Corporation
C- 61/100 β€” 88.2% 2.3% -2.25% $10.03B /rgen-vs-ibrx β†’
TWST
Twist Bioscience Corporation
D 47/100 β€” 94.2% -11.7% -15.54% $10.13B /twst-vs-ibrx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001326110 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ImmunityBio Inc. (IBRX) reported GAAP revenue of $113.3M (+668.3% vs. FY2024 revenue of $14.7M , and +18113.5% cumulative change since FY2023) , GAAP net income of -$351.5M, operating cash flow of -$304.9M, and free cash flow of -$308.8M (+22.4% YoY). On the balance sheet, IBRX closed FY2025 with $501.9M in total assets against $450.7M in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $113.3M -$351.5M -$304.9M -$308.8M $501.9M $450.7M
FY2024 (FY) 2024-12-31 $14.7M -$413.6M -$391.2M -$398.1M $382.9M $392.0M
FY2023 (FY) 2023-12-31 $622.0K -$583.9M -$366.8M -$366.8M $5.09B $1.19B

3. IBRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ImmunityBio Inc. (NASDAQ: IBRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $7.95 (-4.10% 1D, market cap $8.79B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IBRX ranks #619 in composite RQD confidence.

How does IBRX compare to PCVX and KRYS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IBRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.3%. By comparison, PCVX (Vaxcyte Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.76B) and KRYS (Krystal Biotech Inc.) posts a B grade (73/100 RQD, P/E 46.9x, ROIC 16.5%, cap $9.84B). Among the 5-stock peer group, KRYS leads on earnings multiple (46.9x) while KRYS leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IBRX?

Per IBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326110), ImmunityBio Inc. generated $113.3M in revenue (+668.3% YoY), -$351.5M in net income, and -$308.8M in free cash flow against $501.9M in total assets and $450.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IBRX trading relative to its 50-day, 200-day, and 52-week technical levels?

IBRX last traded at $7.95 (-4.10% on volume of 9,063,534 shares), positioning the stock -9.14% below its 50-day simple moving average ($8.75) and 0.00% above its 200-day simple moving average ($7.95). Across its 52-week range of $1.95 to $12.43, IBRX sits at the 57.3% percentile with a 14-day RSI of 44.3 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($6.96 to $8.94).

Direct Sub-Reports: IBRX RQD Cockpit IBRX 12M Forecast IBRX Earnings & Move IBRX Dividends & DRIP IBRX Insiders & 13F IBRX Whale Options IBRX Profit Sankey IBRX News & Why
ROARABLE RATING BRIEF β€’ RQD 34/100 (E) βœ“ SEC XBRL & RQD VERIFIED

IBRX β€” ImmunityBio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ImmunityBio Inc. (IBRX) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $7.95 (-4.10% 1D, market capitalization $8.79B).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -27.3%, gross margin of 96.0%, operating margin of -60.0%, and free cash flow yield of -3.33%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (8/20): Incorporates a 1.05x equity beta, Altman Z-Score of 0.45, Piotroski F-Score of 6/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

ImmunityBio Inc. (IBRX) is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances)..3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ImmunityBio Inc. (IBRX) reported $113.3M in annual revenue (up from $14.7M in FY2024, +668.3% YoY) and -$351.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($622.0K revenue, -$583.9M net income) through FY2025, IBRX scaled operating cash flow to -$304.9M and free cash flow to -$308.8M, backed by $501.9M in total assets against $450.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.33% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $1.95 – $12.43 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.05x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: β€” Sector correlations beyond the Health Care sector classification: β€” Second-order bottlenecks: β€” The RQD macro pillar's reference to sector sensitivity is the only source-supported ripple channel.

  • Key Question #1: Can IBRX sustain or expand its -60.0% operating margin and -27.3% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $113.3M and free cash flow of -$308.8M, how will capital allocation balance growth reinvestment against $450.7M in total debt?
  • Key Question #3: How sensitive is IBRX's 29.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.05x)?

IBRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ImmunityBio Inc. (IBRX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to IBRX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IBRX Bull vs. Bear Conversation Board β€” What's Your Call at $7.95?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IBRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IBRX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER β€’ Verified $100K Arena Trader πŸ‚ BULLISH 🎯 Target: $10.86 (+31.0%)
πŸ“Œ Pinned Debate

Institutional whale 13F flow scores 11 of 20 and the stock recently moved higher on Oct 9 and overnight, with reported revenue growing

Don't sleep on IBRX's setup in Health Care. Institutional whale 13F flow scores 11 of 20 and the stock recently moved higher on Oct 9 and overnight, with reported revenue growing from $0.6M in FY 2023 to $113.3M in FY 2025.. Beta of 1.05 means it moves fast when momentum turns, and the 5-pillar RQD gauge (34/100) backs up the fundamental quality.

SectorRotator πŸ‚ BULL

@MeanReversion_88 Fair point on 29.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (96.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $6.80 (-18.0%)
Spot @ $8.29

ROIC of -27.3%, an FCF yield of -3.33%, an Altman Z-Score of 0.45, and FY 2025 operating income of -$256.0M leave the rating at 37 with

Fading this rally in IBRX at $8.29. ROIC of -27.3%, an FCF yield of -3.33%, an Altman Z-Score of 0.45, and FY 2025 operating income of -$256.0M leave the rating at 37 with a Roarable Sell label.. With a beta of 1.05 and the stock sitting at $8.29 (52-wk range $1.83–$12.43), the easy multiple expansion is already priced in.

LIVE TAPE